BR112014000485A2 - derivados de azetidina para o tratamento de transtornos relacionados à melanina - Google Patents

derivados de azetidina para o tratamento de transtornos relacionados à melanina

Info

Publication number
BR112014000485A2
BR112014000485A2 BR112014000485A BR112014000485A BR112014000485A2 BR 112014000485 A2 BR112014000485 A2 BR 112014000485A2 BR 112014000485 A BR112014000485 A BR 112014000485A BR 112014000485 A BR112014000485 A BR 112014000485A BR 112014000485 A2 BR112014000485 A2 BR 112014000485A2
Authority
BR
Brazil
Prior art keywords
melanin
treatment
related disorders
azetidine derivatives
azetidinyl
Prior art date
Application number
BR112014000485A
Other languages
English (en)
Inventor
Lars Anders Mikael Johansson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112014000485A2 publication Critical patent/BR112014000485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "derivados de azetidina para o tratamento de transtornos relacionados à melanina". a presente invenção refere-se aos compostos de azetidinila da fórmula i, como descrito aqui, composições farmacêuticas compreendendo um composto de azetidinila, e um método de usar um composto de azetidinila no tratamento ou profilaxia de uma doença ou condição relacionadas ao hormônio concentrador de melanina.
BR112014000485A 2011-07-15 2012-07-13 derivados de azetidina para o tratamento de transtornos relacionados à melanina BR112014000485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161508133P 2011-07-15 2011-07-15
PCT/GB2012/051666 WO2013011285A1 (en) 2011-07-15 2012-07-13 Azetidine derivatives for treatment of melanin related disorders

Publications (1)

Publication Number Publication Date
BR112014000485A2 true BR112014000485A2 (pt) 2017-01-10

Family

ID=46579245

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000485A BR112014000485A2 (pt) 2011-07-15 2012-07-13 derivados de azetidina para o tratamento de transtornos relacionados à melanina

Country Status (14)

Country Link
US (1) US8685958B2 (pt)
EP (1) EP2731950A1 (pt)
JP (1) JP2014520839A (pt)
KR (1) KR20140057263A (pt)
CN (1) CN103857682A (pt)
AR (1) AR087181A1 (pt)
AU (1) AU2012285552A1 (pt)
BR (1) BR112014000485A2 (pt)
CA (1) CA2841645A1 (pt)
MX (1) MX2014000616A (pt)
RU (1) RU2014101104A (pt)
TW (1) TW201311695A (pt)
UY (1) UY34194A (pt)
WO (1) WO2013011285A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3535244A1 (en) 2016-11-02 2019-09-11 Abbvie Deutschland GmbH & Co. KG Spiro-compounds as s1p modulators
KR102616949B1 (ko) 2017-09-14 2023-12-22 다이이찌 산쿄 가부시키가이샤 고리형 구조를 갖는 화합물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4212867A (en) 1977-03-03 1980-07-15 Philagro 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
CA2494102A1 (en) 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
US20070185079A1 (en) 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
ATE432926T1 (de) 2004-07-26 2009-06-15 Lilly Co Eli Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung
JP5057982B2 (ja) 2004-10-18 2012-10-24 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体阻害剤、製造及び治療的使用
CA2589678A1 (en) 2004-12-17 2006-06-22 Eli Lilly And Company Novel mch receptor antagonists
US20080306055A1 (en) 2004-12-21 2008-12-11 Astrazeneca Ab Heterocyclic Mchr1 Antagonists And Their Use In Therapy
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
BRPI0610907A2 (pt) 2005-05-31 2008-12-02 Astrazeneca Ab composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
JP2009501217A (ja) 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
US20090076064A1 (en) 2006-01-06 2009-03-19 Astrazeneca Ab Compounds
AU2007275301A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
EP2121703A4 (en) 2006-08-18 2011-12-28 Astrazeneca Ab THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
CN101558075A (zh) 2006-12-14 2009-10-14 伊莱利利公司 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途
CA2673654A1 (en) * 2007-01-10 2008-07-17 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
EP2148931A2 (en) 2007-04-17 2010-02-03 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
KR101194467B1 (ko) 2007-08-22 2012-10-24 에프. 호프만-라 로슈 아게 Ｎｋ3 수용체 길항제로서의 피롤리딘 아릴-에터
RU2477720C2 (ru) 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях
WO2009135842A1 (en) 2008-05-08 2009-11-12 Evotec Neurosciences Gmbh Azetidines and cyclobutanes as histamine h3 receptor antagonists
US20110071129A1 (en) * 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
WO2011037771A1 (en) * 2009-09-23 2011-03-31 Merck Sharp & Dohme Corp. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
MX2012015102A (es) 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.

Also Published As

Publication number Publication date
CA2841645A1 (en) 2013-01-24
JP2014520839A (ja) 2014-08-25
EP2731950A1 (en) 2014-05-21
US20130184250A1 (en) 2013-07-18
RU2014101104A (ru) 2015-08-27
UY34194A (es) 2013-02-28
KR20140057263A (ko) 2014-05-12
AR087181A1 (es) 2014-02-26
MX2014000616A (es) 2014-02-27
US8685958B2 (en) 2014-04-01
TW201311695A (zh) 2013-03-16
CN103857682A (zh) 2014-06-11
AU2012285552A1 (en) 2014-02-27
WO2013011285A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
BR112015001618A2 (pt) composições fungicidas
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
BR112012012903A2 (pt) compostos de espiropiperidina
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112015020998A2 (pt) compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112014009391A2 (pt) dosagem faseada de clopidogrel
BR112014018879A8 (pt) Composto e composição farmacêutica e combinação compreendendo dito composto
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
CR20110255A (es) Nuevos compuestos 578
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
BR112013024171A2 (pt) método para o tratamento e prevenção de uma condição neurodegenerativa
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
TN2014000112A1 (en) Ep1 receptor ligands
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]